| | Prevention | Treatment |
| Viral attachment ↓ [1, 24, 29, 32, 68–70];
viral internalization ↓ [1, 24, 29, 32, 68–70] | RSV entry ↓ [24, 32–49] |
| | IFN-β, TNF-α production → viral replication ↓[1, 24, 29, 32, 54, 69, 70] | RSV replication ↓ [32–49, 51–55, 57] |
| | IFN-γ production → RSV viral infection ↓ [30, 31, 50, 57, 67] | Syncytium formation of RSV ↓ [26] |
| | The survival of human lung epithelial cells ↑ [31] | Lung inflammation ↓ [30, 50–52, 54–56, 67, 68] |
| | Activate the immune system [30, 50, 57] | F protein expression of RSV ↓ [50] |
| Blocked proinflammatory gene expression [31, 54, 68]
(in the human alveolar epithelial cell line) | Viral loads in serum and lung tissue ↓ [51–54, 67];
no adverse reaction was found [53, 55] |
|
|
